MedTrace Logo

Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)

NCT02713542 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-08-13

Study results available
· View outcomes & findings →

Summary

This study is primarily investigating the effectiveness of Autologous Conditioned Plasma (ACP) Intra-articular (IA) in patients with Osteoarthritis (OA) in the knee.

Conditions

Interventions

DEVICE

ACP

Autologous Conditioned Plasma

OTHER

Placebo

Three Normal Saline IA injections of 3-8 mL at 1-week intervals.

Sponsors & Collaborators

  • Arthrex, Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick Smith, MD · Columbias Orthopedic Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-07-02
Completion
2018-08-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02713542 on ClinicalTrials.gov